Bruce Neil Dawson, a director and the company's Chief Sales and CS Officer, reported a sale of 350 common shares of IBEX Ltd on 08/26/2025 at an average price of $29.13 per share. The sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units and is described as required, not a discretionary trade. After the transaction the reporting person beneficially owned 5,257 shares. The Form 4 was filed as an individual report and signed by an attorney-in-fact.
IBEX Limited reported revenue of $558.3 million for the fiscal year ended June 30, 2025, a 9.8% increase over the prior year, and net income of $36.9 million, up 9.5% from $33.7 million. The company attributed growth to new client wins, expansion in offshore and nearshore capacity, and revenue gains in Retail & E-commerce, HealthTech, Travel, Transportation & Logistics, while FinTech and Telecommunications declined. Fully diluted EPS rose to $2.36 from $1.84, helped by higher net income and fewer diluted shares outstanding.
IBEX operates a global delivery model with 30 centers and approximately 33,000 employees as of June 30, 2025, derives 96% of revenue from U.S. customers, and notes concentration risk with its top three clients representing 26% of revenue and the top client about 11%. Management emphasizes a technology-led strategy built around the Wave iX platform and AI initiatives, while disclosing material risks including client concentration, seasonality, cybersecurity, regulatory and tax considerations, debt covenants, and dependence on third-party telecom and internet channels.
IBEX Limited filed a current report to furnish its latest earnings announcement. On September 11, 2025, the company issued a press release sharing financial results for its fourth quarter and full fiscal year ended June 30, 2025. The press release, which contains the detailed numbers and commentary, is attached as Exhibit 99.1.
The company notes that this earnings information is being furnished rather than filed, which limits certain legal liabilities under securities laws. No other corporate actions or material events are described in this report beyond the release of the quarterly and full-year results.
IBEX Ltd director and Chief People Officer Paul Joseph Inson reported a sale of 10,000 common shares on 08/22/2025. The shares were sold in multiple trades at prices ranging from $30.00 to $30.13, with a weighted average sale price reported as $30.0013. After the sale, the reporting person beneficially owned 7,352 shares directly. The filing also indicates the transaction was made pursuant to a prearranged plan intended to satisfy Rule 10b5-1(c), and the filer offers to provide trade-by-trade pricing details upon request.
IBEX Limited reported a proposed sale of 10,000 common shares through RBC Capital Markets with an approximate aggregate market value of $300,013. The filing states the shares represent stock grants acquired on 04/20/2022 from the issuer and that the sale is expected on 08/22/2025 on NASDAQ. The filing shows 13,372,404 shares outstanding, and no other sales by the reporting person in the past three months are reported. The filer also affirms they are not aware of any undisclosed material adverse information and notes the legal warning about intentional misstatements.
IBEX Ltd (IBEX) Form 4 filing discloses two open-market sales by Chief Executive Officer and Director Robert Thomas Dechant on 2 and 3 July 2025. The transactions involved a total of 5,000 common shares sold at $30.00 per share, producing proceeds of roughly $150,000. Following the dispositions, Dechant’s direct ownership declined from 198,633 to 193,633 shares, a reduction of about 2.5% of his previously held stake. No derivative security activity was reported, and the filing was submitted individually on 3 July 2025.
The modest size of the sale relative to Dechant’s remaining holdings suggests routine portfolio management rather than a wholesale change in insider sentiment. Nonetheless, any CEO sale can attract investor attention, particularly when not explicitly tied to a pre-arranged 10b5-1 trading plan (the form does not indicate such a plan was in place).